Handelsavisen
prelaunch
Companies Healthcare VERU.O
VE
VERU.O NASDAQ Pharmaceuticals & Medical Research

Veru Inc

$2,46
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
39,4M USD
P/E
EV / Rev
Div yield
Op margin
ROE
-22,2 %
Net margin
Debt / equity
0,22
Beta
52w range
Volume
Day range
Prev close
Open
$2,32
Next earnings
2026-11-09
Ex-dividend
TR 1Y
About

Veru Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for women's health and urology.

Business. Veru Inc (VERU.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As specific segment and geographic data are not provided, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.

Classification99 %
SectorHealth Care
Industry groupPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target24,50

Analyst recommendations

2 analysts · consensus Buy
Buy2
Hold0
Sell0
12-month price target
24,50
Consensus of sell-side coverage.
Upcoming events
  • EarningsFY 2026 earnings (expected)2026-11-09 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
2 analysts · indicative
Ownership
BlackRock Institutional Trust Company, N.A.
largest disclosed fund holder
Profitability
-22,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning VERU.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to VERU.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsFY 2026 earnings (expected)2026-11-09 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Veru Inc (VERU.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As specific segment and geographic data are not provided, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.

    Classification99 %
    SectorHealth Care
    Industry groupPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    Veru Inc has a market capitalization of $33.55 million and a price-to-book ratio of 0.74, indicating that the company is trading at a discount to its book value. The company's liquidity position is strong, with a current ratio of 4.72 and $34.74 million in cash and equivalents, which provides a buffer against short-term obligations. The debt-to-equity ratio of 0.22 suggests a conservative capital structure with limited leverage.

    The company's profitability metrics are negative, with a return on equity of -22.18% and a return on assets of -13.96%, indicating that it is not generating returns for shareholders or effectively utilizing its assets. The operating and net losses of $8.89 million and $10.03 million, respectively, highlight the company's ongoing financial challenges. These results are below the industry norms for profitability and returns, which typically require positive ROE and ROA figures for long-term sustainability.

    Veru Inc's revenue concentration and geographic exposure are not disclosed in the available data, making it difficult to assess the company's risk profile from a segment or regional perspective. The absence of detailed segment reporting limits the ability to evaluate the performance of different product lines or geographic regions.

    The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. The negative operating and free cash flows of $11.67 million and $8.68 million, respectively, indicate that the company is not generating sufficient cash to fund operations or expansion. The capital expenditure of $40,660 is minimal, suggesting limited investment in long-term growth initiatives.

    The risk assessment for Veru Inc indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's strong cash position and low debt levels reduce the likelihood of near-term financial distress. However, the ongoing net losses and negative cash flows pose long-term sustainability risks that could necessitate future equity or debt financing.

    Recent events and filings for Veru Inc do not provide specific details on recent developments, but the company's financial performance and analyst estimates suggest a mixed outlook. The mean price target of $24.50 and a strong buy recommendation from analysts indicate some optimism about the company's future. However, the current financial metrics and operational performance suggest that significant improvements are needed to justify such high price targets.

    Key takeaways
    • Veru Inc is trading at a significant discount to its book value, with a price-to-book ratio of 0.74.
    • The company has a strong liquidity position, with a current ratio of 4.72 and $34.74 million in cash and equivalents.
    • Veru Inc is experiencing negative profitability, with a return on equity of -22.18% and a return on assets of -13.96%.
    • Analysts have a generally positive outlook, with a mean price target of $24.50 and a strong buy recommendation.
    • The company's financial performance and operational metrics suggest a need for significant improvements to justify the high price targets.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-02-11
    Q4 2025 · Quarter highlights
    Open report →

    Operating income −234,0% YoY; Net income +40,4% YoY.

    Revenue
    Operating income-$5.4M−234,0 % YoY
    Net income-$5.3M+40,4 % YoY
    Free cash flow-$5.3M−203,8 % YoY
    EPS
    Operating cash flow-$6.2M+45,6 % YoY
    Financials
    Income statement
    Revenue
    Gross profit
    Operating income-$5.4M
    Net income-$5.3M
    Balance sheet
    Total assets$47.6M
    Total liabilities$10.4M
    Total equity$37.1M
    Cash & equivalents$33.0M
    Long-term debt$0.00
    Cash flow
    Operating cash flow-$6.2M
    CapEx$0.00
    Free cash flow-$5.3M
    SBC
    Highlights
    • Operating income −234,0% YoY
    • Net income +40,4% YoY
    • Free cash flow −203,8% YoY

    Valuation TTM

    Market price
    $2,46
    Market cap
    $33.5M
    Enterprise value
    $8.5M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    0.7x
    P / Tangible book
    0.7x
    Tangible book
    $45.2M
    Net cash
    $25.0M
    Current ratio
    4.7
    Debt / equity
    0.2
    ROA
    -14.0%
    ROE
    -22.2%
    Cash conversion
    116.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryPharmaceuticals & Medical Research15,2B node revenueKLAR 23,0%BNTX 21,4%EXEL 15,2%MDGL 6,3%INSM 4,0%VCYT 3,4%MDXG 2,8%AVIR 2,3%Other 21,6%
    Source: company disclosures · own-taxonomy revenue-covered setVERU 0,1% · rank #48 of 109

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs VERU · multiples and returns
    KL
    KLAR
    KLAR.ST
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BN
    BNTX
    Biontech SE
    $92,25
    23,3B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    EX
    EXEL
    Exelixis Inc
    $55,06
    14,7B USD
    P/E
    19,5x
    vs self
    Div yield
    vs self
    ROE
    40,4 %
    +62,6 vs self
    MD
    MDGL
    Madrigal Pharmaceuticals Inc
    $482,00
    11,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -47,8 %
    -25,7 vs self
    IN
    INSM
    Insmed Inc
    $107,46
    23,0B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -160,2 %
    -138,0 vs self
    VC
    VCYT
    Veracyte Inc
    $45,30
    3,6B USD
    P/E
    55,5x
    vs self
    Div yield
    vs self
    ROE
    5,1 %
    +27,3 vs self
    MD
    MDXG
    Mimedx Group Inc
    $4,27
    636,0M USD
    P/E
    11,1x
    vs self
    Div yield
    vs self
    ROE
    18,9 %
    +41,1 vs self
    AV
    AVIR
    Atea Pharmaceuticals Inc
    $4,61
    P/E
    vs self
    Div yield
    vs self
    ROE
    -57,5 %
    -35,3 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -1,20
    Predicted surprise
    -0,01
    Beat probability
    45 %
    Analysts
    2
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    revision ratio -0,01 · as of 2026-05-17 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-1,20
    Revenueno estimateno estimate0 USD
    Operating incomeno estimateno estimate-29,4M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy1
    Buy1
    Hold0
    Sell0
    Strong sell0
    12-month price target$24,50 · Median $24,50
    Low $24,00High $25,00
    Operating income · consensus-29,4M USD
    EPS surprise
    −29,7 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$24,00
    Mean$24,50
    Median$24,50
    High$25,00
    Spot$2,46
    +897.9 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-22,2 %Above median
    D/E0,22Bottom quartile
    Cash Conv1,16Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 1 707 000 sh19 grants8 insiders
    • Greco MicheleChief Admin Officer and CFO · Common Stock Option → Common StockAcquired 164 000 @ $2,25grant · 2026-05-04
    • STEINER MITCHELL SHUSTERDirector, President and CEO · Common Stock Option → Common StockAcquired 604 000 @ $2,25grant · 2026-05-04
    • Lu LucyDirector · Common Stock Option → Common StockAcquired 104 000 @ $2,25grant · 2026-05-04
    • BARNETTE K GARYChief Scientific Officer · Common Stock Option → Common StockAcquired 160 000 @ $2,25grant · 2026-05-04
    • FISCH HARRYDirector, Chief Corporate Officer · Common Stock Option → Common StockAcquired 160 000 @ $2,25grant · 2026-05-04
    • Rankowitz Michael LDirector · Common Stock Option → Common StockAcquired 100 000 @ $2,25grant · 2026-05-04
    • Hyun GraceDirector · Common Stock Option → Common StockAcquired 97 000 @ $2,25grant · 2026-05-04
    • Katzovitz Loren MarkDirector · Common Stock Option → Common StockAcquired 102 000 @ $2,25grant · 2026-05-04
    • Greco MicheleChief Admin Officer and CFO · Common Stock Option → Common StockAcquired 27 000 @ $2,49grant · 2025-12-05
    • BARNETTE K GARYChief Scientific Officer · Common Stock Option → Common StockAcquired 27 000 @ $2,49grant · 2025-12-05
    • Rankowitz Michael LDirector · Common Stock Option → Common StockAcquired 3 000 @ $2,49grant · 2025-12-05
    • Katzovitz Loren MarkDirector · Common Stock Option → Common StockAcquired 6 000 @ $2,49grant · 2025-12-05
    • STEINER MITCHELL SHUSTERDirector, President and CEO · Common Stock Option → Common StockAcquired 100 000 @ $2,49grant · 2025-12-05
    • Hyun GraceDirector · Common Stock Option → Common StockAcquired 6 000 @ $2,49grant · 2025-12-05
    • Lu LucyDirector · Common Stock Option → Common StockAcquired 4 000 @ $2,49grant · 2025-12-05
    • FISCH HARRYDirector, Chief Corporate Officer · Common Stock Option → Common StockAcquired 27 000 @ $2,49grant · 2025-12-05
    • Lu LucyDirector · Common Stock Option → Common StockAcquired 6 000 @ $3,89grant · 2025-10-01
    • Hyun GraceDirector · Common Stock Option → Common StockAcquired 3 000 @ $3,89grant · 2025-10-01
    • Rankowitz Michael LDirector · Common Stock Option → Common StockAcquired 7 000 @ $3,89grant · 2025-10-01

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • Veru Inc Market data — financials · 2026-05-29
    • Veru Inc Market data — analyst estimates · 2026-05-29
    • Veru Inc Market data — ESG · 2026-05-29

    Ownership & reference

    Top holders

    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$6M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$0M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$1M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
    • Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M

    Insider activity

    — missing data

    Short positioning

    1.4Mshares short+105.7% vs prior
    4.07days to cover
    40.4%short of daily vol
    514fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    VERU.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise-0,01Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Debt-to-equity (FY 2025-12-31): 0.28xDerived (calculated)
    • Current ratio (FY 2025-12-31): 5.16xDerived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 24.0%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 39.4%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 19.4%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -20.9%Derived (calculated)
    • Shareholders' equity (annual): USD 37.12MSEC XBRL filing
    • Shares outstanding (annual): 16.05MSEC XBRL filing
    • Current assets (annual): USD 36.81MSEC XBRL filing
    • Total liabilities (annual): USD 10.44MSEC XBRL filing
    • Total assets (annual): USD 47.57MSEC XBRL filing
    • Current liabilities (annual): USD 7.13MSEC XBRL filing
    • Cash & equivalents (annual): USD 32.99MSEC XBRL filing
    • Operating cash flow (YoY) (2025-09-30 vs 2024-09-30): -38.6%Derived (calculated)
    • Net income (YoY) (2025-09-30 vs 2024-09-30): 39.9%Derived (calculated)
    • Capex (YoY) (2025-09-30 vs 2024-09-30): -99.3%Derived (calculated)
    • EPS (basic) (YoY) (2025-09-30 vs 2024-09-30): 44.6%Derived (calculated)
    • R&D expense (YoY) (2025-09-30 vs 2024-09-30): 22.0%Derived (calculated)
    • Operating income (YoY) (2025-09-30 vs 2024-09-30): 31.6%Derived (calculated)
    • Capex (annual): USD 1.08KSEC XBRL filing
    • Operating cash flow (annual): USD -30.04MSEC XBRL filing
    • R&D expense (annual): USD 15.59MSEC XBRL filing
    • Net income (annual): USD -22.73MSEC XBRL filing
    • Total operating expenses (annual): USD 35.53MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-11-09EVENTUpcomingFY 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-04FILINGFORM 8-K →
    2026-05-13FILINGFORM 10-Q →
    2026-05-13FILING8-K filing →
    2026-05-04 00:00 UTCINSIDER8 insider transactions — 2026-05 8 derivative
    2026-05-04INSIDERGreco Michele acquired 164.0k sh Common Stock Option — Chief Admin Officer and CFO
    2026-05-04INSIDERSTEINER MITCHELL SHUSTER acquired 604.0k sh Common Stock Option — Director, President and CEO
    2026-05-04INSIDERKatzovitz Loren Mark acquired 102.0k sh Common Stock Option — Director
    2026-05-04INSIDERHyun Grace acquired 97.0k sh Common Stock Option — Director
    2026-05-04INSIDERRankowitz Michael L acquired 100.0k sh Common Stock Option — Director
    2026-05-04INSIDERLu Lucy acquired 104.0k sh Common Stock Option — Director
    2026-05-04INSIDERBARNETTE K GARY acquired 160.0k sh Common Stock Option — Chief Scientific Officer
    2026-05-04INSIDERFISCH HARRY acquired 160.0k sh Common Stock Option — Director, Chief Corporate Officer
    2026-03-13FILINGFORM 8-K →
    2026-02-11 06:30 UTCEARNINGSQuarterly results — Q4 2025 Net USD -5.3M
    2026-02-11FILINGFORM 10-Q →
    2026-02-11FILING8-K filing →
    2026-01-28FILINGDEF 14A filing →
    2025-12-17 06:30 UTCEARNINGSQuarterly results — Q3 2025 Net USD 1.5M
    2025-12-17 06:30 UTCEARNINGSAnnual results — FY 2025 Net USD -22.7M
    2025-12-17FILINGFORM 10-K →
    2025-12-17FILING8-K filing →
    2025-12-05 00:00 UTCINSIDER8 insider transactions — 2025-12 8 derivative
    2025-12-05INSIDERLu Lucy acquired 4.0k sh Common Stock Option — Director
    2025-12-05INSIDERFISCH HARRY acquired 27.0k sh Common Stock Option — Director, Chief Corporate Officer
    2025-12-05INSIDERBARNETTE K GARY acquired 27.0k sh Common Stock Option — Chief Scientific Officer
    2025-12-05INSIDERRankowitz Michael L acquired 3.0k sh Common Stock Option — Director
    2025-12-05INSIDERKatzovitz Loren Mark acquired 6.0k sh Common Stock Option — Director
    2025-12-05INSIDERSTEINER MITCHELL SHUSTER acquired 100.0k sh Common Stock Option — Director, President and CEO
    2025-12-05INSIDERHyun Grace acquired 6.0k sh Common Stock Option — Director
    2025-12-05INSIDERGreco Michele acquired 27.0k sh Common Stock Option — Chief Admin Officer and CFO
    2025-10-30FILING8-K filing →
    2025-10-30FILING424B5 filing →
    2025-10-29FILING424B5 filing →
    2025-10-01 00:00 UTCINSIDER3 insider transactions — 2025-10 3 derivative
    2025-10-01INSIDERRankowitz Michael L acquired 7.0k sh Common Stock Option — Director
    2025-10-01INSIDERLu Lucy acquired 6.0k sh Common Stock Option — Director
    2025-10-01INSIDERHyun Grace acquired 3.0k sh Common Stock Option — Director
    2025-08-12 06:30 UTCEARNINGSQuarterly results — Q2 2025 Net USD -7.3M
    Showing the 40 most recent of 50 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage